Urinary incontinence: pharmacotherapy options.

Urinary incontinence: pharmacotherapy options.

Item
http://www.wikidata.org/entity/Q37884579
Coadministration of low-dose serotonin/noradrenaline reuptake inhibitor (SNRI) duloxetine with α 2-adrenoceptor blockers to treat both female and male mild-to-moderate stress urinary incontinence (SUI)Applications and implications of heparin and protamine in tissue engineering and regenerative medicine.Serotonin and noradrenaline reuptake inhibitors improve micturition control in mice2012 update: guidelines for adult urinary incontinence collaborative consensus document for the canadian urological associationPseudoephedrine for the treatment of clozapine-induced incontinence.Regenerative medicine based applications to combat stress urinary incontinence.Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats.Risk factors for urinary, fecal, or dual incontinence in the Nurses' Health Study.Can we prevent incontinence? ICI-RS 2011.
P2860

Urinary incontinence: pharmacotherapy options.

Item
http://www.wikidata.org/entity/Q37884579
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Urinary incontinence: pharmacotherapy options.
@en
Urinary incontinence: pharmacotherapy options.
@nl
type
label
Urinary incontinence: pharmacotherapy options.
@en
Urinary incontinence: pharmacotherapy options.
@nl
prefLabel
Urinary incontinence: pharmacotherapy options.
@en
Urinary incontinence: pharmacotherapy options.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Urinary incontinence: pharmacotherapy options.
@en
P2093
P2860
P304
P31
P356
10.3109/07853890.2011.564203
P407
P433
P478
P50
P577
P698
P921